Skip to main content
. 2013 Feb 27;304(9):C833–C843. doi: 10.1152/ajpcell.00036.2012

Fig. 1.

Fig. 1.

A: expression of canonical transient receptor potential (TRPC) mRNA relative to cyclophilin B in distal pulmonary arterial smooth muscle cells (PASMCs) treated with bone morphogenetic protein (BMP) 2 (5, 10, 50, 100, or 200 ng/ml) or vehicle (control; 4 mM HCl with 0.1% BSA) for 60 h as determined by real-time quantitative PCR. Values are means ± SE (n = 4 in each group). *P < 0.05 vs. control. B: expression of TRPC mRNA relative to cyclophilin B in distal PASMCs treated with 50 ng/ml BMP2 or vehicle (control) for 24, 48, or 60 h as determined by real-time quantitative PCR. Values are means ± SE (n = 3 in each group). *P < 0.05 vs. control.